The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses
Abstract
Adjuvants enhance antibody response against vaccination. We compared the ability of MF59-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59-adjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59-adjuvanted vaccine. Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the elderly population, MF59-adjuvanted influenza vaccines enhance seroconversion and seroprotection rates compared with non-adjuvanted vaccines240 and induce broad serological protection against strains with antigenic drift241.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [241]
Citations
Cites
Rowe, T., Abernathy, R. A., Hu‐Primmer, J., Thompson, W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 812
Influenza vaccine: The challenge of antigenic drift
Carrat, F., & Flahault, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 704
(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 663
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J., Zambon, M. C. F. A., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 286
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
DONATO, S. D., Granoff, D. M., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 185
BEYER, W. E. P., Palache, A. M., Lüchters, G., Nauta, J. J. P., & Osterhaus, A. D. M. E. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.024 · Cited by 179
Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 174
Self-citationGasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 128
Self-citationGIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119
Muszkat, M., Yehuda, A. B., Schein, M. H., Friedlander, Y., Naveh, P., Greenbaum, E., Schlesinger, M., Levy, R., Zakay‐Rones, Z., & Friedman, G. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200005)61:1 · Cited by 44
Baldo, V., Baldovin, T., Floreani, A., Fragapane, E., Trivello, R., & The Family Medicine Group (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9100-4 · Cited by 43
Neutralization enzyme immunoassay for influenza virus
Benne, C. A., Harmsen, M., de Jong, J. C., & Kraaijeveld, C. A. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.987-990.1994 · Cited by 37
Ansaldi, F., Icardi, G., Gasparini, R., Campello, C., Puzelli, S., Bella, A., Donatelli, I., Salmaso, S., & Crovari, P. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.3027-3029.2005 · Cited by 26
Self-citationIorio, A. M., Neri, M., Lepri, E., Camilloni, B., Basileo, M., Sigismondi, N., Fabiani, C., Calzoletti, L., Puzelli, S., & Donatelli, I. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.037 · Cited by 21
Kojimahara, N., Maeda, A., KASE, T., & Yamaguchi, N. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.009 · Cited by 19
Ansaldi, F., Bacilieri, S., Banfi, F., Durando, P., Sticchi, L., Icardi, G., & Gasparini, R. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.1.162-164.2006 · Cited by 13
Self-citation
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Advances in aluminum hydroxide-based adjuvant research and its mechanism
Peng, H., Zou, Y., & Hu, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004026 · Cited by 415
Traditional and New Influenza Vaccines
Wong, S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 385
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 327
Calabrό, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., Gregorio, E. D., O’Hagan, D. T., Baudner, B. C., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 215
Metadata
- Authors
- Ansaldi, F., Bacilieri, S., Durando, P., Sticchi, L., Valle, L., Montomoli, E., Icardi, G., Gasparini, R., & Crovari, P.
- Affiliations
- Centro interuniversitario per la ricerca sull'influenza e le altre infezioni trasmissibili (IT)
- University of Siena (IT)
- Corresponding author
- Ansaldi, Filippo
- ORCID
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 26
- Issue
- 12
- Pages
- 1525-1529
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2163192885
- Cited by
- 134
- References
- 17
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 5 · 2022: 7 · 2021: 14 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 3 · 2013: 9 · 2012: 9
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- MF59 adjuvant, influenza vaccination, cross-protection, H3N2, antigenic drift, neutralizing antibodies, hemagglutination inhibition antibodies, secondary immune response, older adults, subunit vaccine, immunogenicity
- MeSH terms
- Adjuvants, Immunologic, Aged, Antibodies, Viral, Cross Reactions, Hemagglutination Inhibition Tests, Humans, Influenza Vaccines, Middle Aged, Neutralization Tests, Polysorbates, Squalene, Influenza A Virus, H3N2 Subtype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
